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Abstract
Objective: To investigate the relative predictive value of circulating immune cell markers for car-
diovascular mortality in ambulatory adults without cardiovascular disease.
Methods: We analyzed data of participants enrolled in the National Health and Nutrition Examination
Survey from January 1, 1999, to December 31, 2010, with the total leukocyte count within a normal
range (4000-11,000 cells/mL [to convert to cells 109/L, multiply by 0.001]) and without cardio-
vascular disease. The relative predictive value of circulating immune cell markers measured at
enrollmentdincluding total leukocyte count, absolute neutrophil count, absolute lymphocyte count,
absolute monocyte count, monocyte-lymphocyte ratio (MLR), neutrophil-lymphocyte ratio, and C-
reactive proteindfor cardiovascular mortality was evaluated. The marker with the best predictive
value was added to the 10-year atherosclerotic cardiovascular disease (ASCVD) risk score to estimate
net risk reclassification indices for 10-year cardiovascular mortality.
Results: Among 21,599 participants eligible for this analysis, the median age was 47 years (inter-
quartile range, 34-63 years); 10,651 (49.2%) participants were women, and 10,713 (49.5%) were self-
reported non-Hispanic white. During a median follow-up of 9.6 years (interquartile range, 6.8-13.1
years), there were 627 cardiovascular deaths. MLR had the best predictive value for cardiovascular
mortality. The addition of elevated MLR (0.3) to the 10-year ASCVD risk score improved the
classification by 2.7%1.4% (P¼.04). Elevated MLR had better predictive value than C-reactive
protein and several components of the 10-year ASCVD risk score.
Conclusion: Among ambulatory US adults without preexisting cardiovascular disease, we found that
MLR had the best predictive value for cardiovascular mortality among circulating immune markers.
The addition of MLR to the 10-year risk score significantly improved the risk classification of
participants.
ª 2020 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2020;nn(n):1-10
A ctivation of the immune system hasbeen described in cardiovasculardiseases, such as atherosclerosis,
acute coronary syndrome, and heart fail-
ure.1-4 The associated immune markers
may have prognostic significance to detect
long-term cardiovascular events. However,
the widely used cardiovascular risk predic-
tion models do not include any immune
markers.5,6
Circulating immune-inflammatory
markers such as C-reactive protein (CRP),
total leukocyte count, and differential leuko-
cyte count are widely available, and studies
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report their independent association with
adverse cardiovascular outcomes.1-3,7,8 How-
ever, their ability to predict the long-term
risk of cardiovascular mortality in a popula-
tion without cardiovascular disease remains
unknown. Furthermore, no previous study
has compared the relative predictive values
of these circulating immune markers.
Finally, it remains unclear how the predic-
tive value of circulating immune markers
compares with that of traditional cardiovas-
cular risk factors such as age, hypertension,
and dyslipidemia.
We investigated the role of widely avail-
able circulating immune cell markers to pre-
dict cardiovascular mortality in a
representative ambulatory US adult popula-
tion without cardiovascular disease. We hy-
pothesized that circulating immune cell
markers in the normal range are differen-
tially associated with cardiovascular risk.
We aimed to rank their relative predictive
value and to explore how the addition of
these circulating immune cell markers to
current prediction models modifies cardio-
vascular risk classification.
METHODS
The study was conducted following the
Strengthening the Reporting of Observa-
tional Studies in Epidemiology guidelines
(Supplemental Table 1, available online at
http://www.mayoclinicproceedings.org).
Study Design and Participants
The National Health and Nutrition Examina-
tion Survey (NHANES) is a serial cross-
sectional survey designed to gather data
about the health status of the resident civilian
noninstitutionalized US population. The de-
tails of the interview, laboratory evaluation,
and physical examination have been pub-
lished previously9 and are given in the
Supplemental Methods (available online at
http://www.mayoclinicproceedings.org). The
data are linked to the National Death Index
through December 31, 2011. We used pub-
licly available deidentified data. Therefore,
approval from the University of Alabama at
Birmingham Institutional Review Board
was not required. Data from participants
aged 18 years and older from 6 NHANES cy-
cles from 1999 to 2010 were used for the
analysis (Figure 1).
We excluded participants with preexist-
ing cardiovascular disease (self-reported
angina, heart attack, coronary artery disease,
heart failure, stroke, or pacemaker) or total
leukocyte count beyond the normal range
(<4000 cells/mL or >11,000 cells/mL [to
convert to cells 109/L, multiply by
0.001]). Other exclusion criteria are given
in the Supplemental Methods.
Study Variables
Several circulating immune markers, such as
total and differential leukocyte count and
CRP, used in this investigation were avail-
able from the blood sample collected at the
time of the visit to the mobile examination
center during NHANES. Details are given
in the Supplemental Methods and
Supplemental Table 2 (available online at
http://www.mayoclinicproceedings.org). We
computed the neutrophil-lymphocyte ratio
by dividing the absolute neutrophil count
by the absolute lymphocyte count and the
monocyte-lymphocyte ratio (MLR) by
dividing the absolute monocyte count by
the absolute lymphocyte count. Both these
ratios are independently associated with
worse cardiovascular prognosis.10,11
Demographic and Clinical Information
Data on other demographic and clinical
characteristics were collected during either
the interview or the visit to the mobile exam-
ination center. The variable codes and diag-
nostic criteria to define comorbidities are
given in the Supplemental Methods and
Supplemental Table 2.
Study Outcome
Cardiovascular mortality during follow-up
was the outcome for all survival analyses.
Cardiovascular mortality that occurred
within 10 years of the visit to the mobile ex-
amination center was the outcome for all lo-
gistic models. The cause of death was
derived from linked death certificate records
from the National Death Index.12 Details are
given in the Supplemental Methods and
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Supplemental Table 2. Follow-up time was
taken as time from mobile examination cen-
ter date to the date of death or end of mortal-
ity period.
Statistical Analyses
Continuous variables were reported as me-
dians with interquartile ranges (IQRs), and
categorical variables were represented as
counts with proportions. The Wilcoxon
rank sum test and c2 test were used to iden-
tify the differences in baseline characteristics
in continuous and categorical variables,
respectively. We estimated the 10-year
atherosclerotic cardiovascular disease
(ASCVD) and Framingham risk scores for
all participants.5,6 For calculation, partici-
pants younger than 40 years or older than
79 years were considered to be 40 years old
and 79 years old, respectively. The baseline
characteristics of the participants with age
younger than 40 years, 40 to 79 years, and
older than 79 years are given in
Supplemental Table 3 (available online at
http://www.mayoclinicproceedings.org).
The 10-year ASCVD and Framingham risk
scores varied across the NHANES cycle
(Supplemental Table 4, available online at
http://www.mayoclinicproceedings.org).
We assessed the relative predictive value
of circulating immune markers using the
Cox proportional hazards model and the lo-
gistic regression model. Details are given in
the Supplemental Methods. The optimal cut-
off of the circulating immune marker with
the best predictive value for 10-year cardiovas-
cular mortality was estimated using the You-
den and Liu index.13,14 We then evaluated
the independent association of the marker
with the best predictive value at a categorical
cutoff ascertained in the previous step. We
used both the Cox proportional hazards
model and competing risk regression analysis
with noncardiovascular mortality as a
competing risk for cardiovascular mortality
in the adjusted model. The adjusted Cox pro-
portional hazards model included the
following covariates: age, sex, race, hyperten-
sion, hemoglobin, diabetes mellitus, chronic
obstructive pulmonary disease, current
smoking, dyslipidemia, estimated glomerular
filtration rate, malignant disease, obesity, and
NHANES cycle. The variables in multivariate
models were included if they were established
risk factors for cardiovascular events or associ-
ated with inflammation and cardiovascular
mortality. We also included the NHANES cy-
cle as a covariate as sampling strategy changed
in NHANES over the years, which likely led to
variation in 10-year ASCVD risk across the
NHANES cycles. The proportionality assump-
tion was verified using the Schoenfeld resid-
uals.15 We determined whether there was a
dose-response relationship of cardiovascular
mortality with the marker with the best pre-
dictive value. Poisson regression analyses
were used to estimate the incident rate (per
100 person-years) of cardiovascular mortality.
Missing data for obesity (n¼291 [1.4%]) and
estimated glomerular filtration rate (n¼54
[0.3%]) were imputed using multivariate
chained equations with age, sex, and race as
predictors.16 There was no difference in the





• Age <18 years n=26,781
• Missing leukocyte count/CRP n=26,152
• TLC outside normal range/ hematological
   malignancy n=15,706
• Missing data to compute risk score n=3,876
• Pre-existing cardiovascular disease n=2,379
• Pregnant n=1,502





FIGURE 1. Flow diagram for study selection. Normal range of total
leukocyte count (TLC) is defined as 4000 to 11,000 cells/mL (to convert to
cells 109/L, multiply by 0.001). Cardiovascular disease is defined as self-
reported coronary artery disease, heart failure, stroke, or on pacemaker.
CRP, C-reactive protein; HIV, human immunodeficiency virus; NHANES,
National Health and Nutrition Examination Survey.
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in the Cox model between the imputed and
the unimputed variables (Supplemental
Table 5, available online at http://www.
mayoclinicproceedings.org).
We also determined the independent
prognostic importance of all circulating im-
mune markers using the Cox proportional
hazards model to predict cardiovascular
mortality.
Reclassification and Comparison With CRP
and Components of ASCVD and Framing-
ham Risk Scores
We then estimated the net reclassification in-
dex (NRI) after adding the circulating im-
mune marker with the best predictive value
in the same model as the 10-year ASCVD
risk score and the Framingham risk score
with a prespecified cutoff of 5% (low
risk).17 NRI helps compare the discrimina-
tive ability of 2 risk prediction models by lo-
gistic regression.17 The reclassification
indices for both scores were also estimated
after the addition of CRP, given that it is
the most commonly used inflammatory
marker to predict cardiovascular out-
comes.18 Furthermore, we ranked the pre-
dictive value of the components in the 10-
year ASCVD risk score, the Framingham
risk score, and the circulating immune
marker for 10-year cardiovascular mortality.
These factors were ranked by the likelihood
and Wald c2 statistics for the Cox propor-
tional hazards analyses and by the area un-
der the curve and standardized domination
statistic for the logistic regression ana-
lyses.11,12 All statistical analyses were per-
formed in Stata/SE version 15.1
(StataCorp). All P values were 2 sided, with




Among 62,160 participants in 6 NHANES
cycles spanning 1999 to 2010, there were
21,599 participants (34.7%) included in the
analyses (Figure 1). The baseline character-
istics of the study population are given in
the Table.
The median age of the participants was
47 years (IQR, 34-63 years), with 10,651
(49.2%) women and 10,713 (49.5%) self-
identified as non-Hispanic white. The preva-
lence of diabetes mellitus, hypertension, and
dyslipidemia was 13.8%, 52.8%, and 65.0%,
respectively (Table). The median leukocyte
count was 6900 cells/mL (IQR, 5700-8100
cells/mL). The median absolute neutrophil
and monocyte counts were 4000 cells/mL
(IQR, 3100-4900 cells/mL) and 500 cells/mL
(IQR, 400-600 cells/mL), respectively. The
median 10-year ASCVD risk score and Fra-
mingham risk score was 5% (IQR, 1.6%-
16.7%) and 7.4% (IQR, 2.0%-21.9%),
respectively.
The participants in the assembled cohort
were observed for a median of 9.6 years
(IQR, 6.8-13.1 years). Cause of death was
available in 99.8% of participants. There
were 627 deaths due to cardiovascular
causes at an incident rate of 0.29 per 100
person-years (95% CI, 0.27-0.32). Of these,
509 (81.2%) cardiovascular deaths were
within 10 years of follow-up.
Relative Predictive Value of Circulating Im-
mune Markers
The MLR had the best predictive value for
10-year cardiovascular mortality (Figure 2)
in both time to event (using likelihood and
Wald c2 statistics) and logistic regression
analyses (area under the curve and standard-
ized domination statistic). The risk of car-
diovascular mortality was higher with 1 SD
rise of MLR (b¼.34) compared with 1 SD
rise of CRP (b¼.08; Wald c2 for comparison
of b in survival model ¼ 71.30; P<.001).
The optimal cutoff of the MLR to classify pa-
tients with the highest accuracy for the risk
of 10-year cardiovascular mortality using
the Youden index was 0.30 (Supplemental
Figure 1, available online at http://www.
mayoclinicproceedings.org). This cutoff had
a sensitivity and specificity of 55% and
69%. Participants with an elevated MLR
(0.3) had a higher risk of cardiovascular
mortality in the adjusted analysis (hazard ra-
tio, 1.36; 95% CI, 1.15-1.60; P<.001;
Figure 3A) and the competing risk analysis
with noncardiovascular mortality as a
MAYO CLINIC PROCEEDINGS
4 Mayo Clin Proc. n XXX 2020;nn(n):1-10 n https://doi.org/10.1016/j.mayocp.2020.11.027
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by 
Elsevier on May 10, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
competing risk (hazard ratio, 1.29; 95% CI,
1.09-1.52; P¼.003; Figure 3B) (all P<.05).
The effect estimates remained robust in the
adjusted model with unimputed data (haz-
ard ratio, 1.37; 95% CI, 1.15-1.63; P<.001).
There was a dose-response relationship
such that the incidence of cardiovascular
mortality increased by 13% (95% CI, 6-21)
for every 1 unit increase in the MLR in the
adjusted model (Figure 4).
All immune markers except absolute
lymphocyte count were independently asso-
ciated with cardiovascular mortality
(Supplemental Table 6, available online at
http://www.mayoclinicproceedings.org).
Reclassification and Comparison With CRP
and Components of ASCVD and Framing-
ham Risk Scores
Baseline demographic, clinical, and labora-
tory characteristics of participants by low
(<0.3) or elevated (0.3) MLR are given
in Supplemental Table 7 (available online
at http://www.mayoclinicproceedings.org).
The participants with elevated MLR were
older and included a higher representation
of men and non-Hispanic whites and indi-
viduals with hypertension, smoking, and
malignant disease. Participants in the
elevated MLR group had a significantly
higher 10-year ASCVD score (8.3% vs
4.2%; P<.001) and Framingham risk score
(12.1% vs 6.0%; P<.001).
Addition of elevated MLR to the cate-
gorical 10-year ASCVD risk score
correctly up-classified 3.2% of participants
with cardiovascular mortality (49.3% to
52.2%) and incorrectly up-classified 0.4%
of participants with no cardiovascular
mortality (8.8% to 9.2%). There was a
significant improvement in risk classifica-
tion (NRI, 2.71.4; P¼.04; Supplemental
Figure 2A, available online at http://
www.mayoclinicproceedings.org). Adding
elevated CRP to the categorical 10-year
ASCVD risk score had no impact on the
risk classification (NRI, 0.20.0;
P¼.83; Supplemental Figure 2B). Risk
reclassification with addition of other
circulating immune markers to the 10-
year ASCVD risk score with different
TABLE. Baseline Demographic, Clinical, and Laboratory Parameters in the
Assembled NHANES Cohort (1999-2010)a,b,c
Factor Overall (N¼21,599)
Demographic parameters
Age (y) 47.0 (34.0-63.0)
Women 10,651 (49.2)
Race
Non-Hispanic white 10,713 (49.5)
Non-Hispanic black 3887 (18.0)
Mexican American 4660 (21.5)
Other Hispanic 1544 (7.1)
Other race, including multiracial 845 (3.9)
Anthropometry
Weight (kg) 77.8 (66.4-91.0)
Height (m) 1.7 (1.6-1.8)
Body mass index (kg/m2) 27.6 (24.2-31.6)
Comorbidities
Diabetes mellitus 2977 (13.8)
Dyslipidemia 14,082 (65.0)
Hypertension 11,441 (52.8)
Systolic blood pressure (mm Hg) 122.0 (112.0-135.0)
Diastolic blood pressure (mm Hg) 72.0 (64.0-79.0)
Smoking 10,143 (46.9)
Chronic obstructive pulmonary disease 122 (0.6)
Malignant disease 750 (5.7)
Obesity 7104 (33.3)
Laboratory parameters
Hemoglobin (g/dL) 14.4 (13.4-15.4)
Platelet count (cells 106/mL) 260.0 (223.0-305.0)
Estimated GFR (mL/min/1.73 m2)d 99.7 (82.1-122.0)
Circulating immune markers
C-reactive protein (mg/dL) 0.2 (0.1-0.4)
Total leukocyte count (cells 103/mL) 6.9 (5.7-8.1)
Absolute lymphocyte count (cells 103/mL) 2.0 (1.7-2.5)
Absolute neutrophil count (cells 103/mL) 4.0 (3.1-4.9)
Absolute monocyte count (cells 103/mL) 0.5 (0.4-0.6)




Neutrophil-lymphocyte ratio 2.0 (1.5-2.6)
Monocyte-lymphocyte ratio 0.3 (0.2-0.3)
Risk score
10-year ASCVD riske (%) 5.0 (1.6-16.7)
10-year Framingham risk (%) 7.4 (2.0-22.0)
aASCVD, atherosclerotic cardiovascular disease; GFR, glomerular filtration rate; NHANES, Na-
tional Health and Nutrition Examination Survey.
bTo convert hemoglobin values to g/L, multiply by 10; to convert platelet count to cells 109/L,
multiply by 0.001; to convert C-reactive protein values to nmol/L, multiply by 95.24; to convert
white blood cell counts to cells 109/L, multiply by 0.001.
cData are represented as median (25th-75th percentile) or number (%).
dGFR estimated by the Modification of Diet in Renal Disease 4-component study equation.
eFor calculation of 10-year ASCVD risk, participants aged <40 years (n¼7,547 [34.9%]) or >79
years (n¼1,315 [6%]) were considered to be 40 and 79 years old, respectively. Neutrophil-
lymphocyte and monocyte-lymphocyte ratio derived by dividing absolute neutrophil count and
absolute monocyte count by absolute lymphocyte count, respectively.
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statistical models is given in Supplemental
Table 8 (available online at http://www.
mayoclinicproceedings.org).
Similarly, adding elevated MLR to the 10-
year Framingham risk score significantly
improved the reclassification by correctly up-
classifying 4% of participants with cardiovas-
cular mortality (NRI, 4.01.2; P¼.001). Add-
ing elevated CRP had no impact on the risk
classification (NRI, 0.30.7; P¼.67).
Comparing the Relative Predictive Value of
MLR With Components of ASCVD and Fra-
mingham Risk Scores
We ranked the predictive value of the 9 com-
ponents of the 10-year ASCVD risk score and
elevated MLR for cardiovascular mortality.
Age had the highest predictive value in all
models. The MLR ranked fifth and had a
higher predictive value than race, smoking sta-
tus, high-density lipoprotein level, and total
cholesterol concentration in both the time to
event and logistic regression models
(Supplemental Figure 3, available online at
http://www.mayoclinicproceedings.org). Simi-
larly, it ranked fifth compared with the com-
ponents of the Framingham risk score.
DISCUSSION
We found that multiple circulating immune
markers were independently associated with
cardiovascular mortality during a median
follow-up of 9.6 years among ambulatory US
adults without preexisting cardiovascular dis-
ease and a total leukocyte count within the
normal range. Among the available circulating
immune markers, the MLR had the best pre-
dictive value. The MLR significantly improved
the classification power of the 10-year ASCVD
risk score and the Framingham risk score to
predict cardiovascular mortality and per-
formed better than CRP as a predictor. In
addition, it had greater prognostic importance
than traditional cardiovascular risk factors
such as race, smoking status, high-density li-
poprotein level, and total cholesterol
concentration.
Immune cells and inflammatory markers
have an important pathophysiologic role in
cardiovascular diseases. They are influenced
by myocardial stressors such as ischemia,
volume overload, or pressure overload and
by comorbidities commonly associated with
cardiovascular diseases, such as dyslipidemia
and obesity.19,20 At a cellular level, there is
an increasing appreciation of the interplay
between cardiac myocytes and immune cells
during physiologic and pathologic states.
Extant literature suggests that there is an
initial infiltration of blood neutrophils and
then proinflammatory monocytes and
monocyte-derived macrophages to clear
necrotic debris after myocardial injury.21,22
Thereafter, tissue macrophages transition to
a phenotype of inflammation resolution
and tissue repair. This complex inflamma-
tory response, initially directed at myocar-
dial repair, may become dysregulated and
cause adverse cardiac remodeling and
worsen prognosis.23 These observations
lend biologic credence to our findings
whereby both neutrophils and monocytes
were independent risk factors for increased
cardiovascular mortality.
The critical role of monocytes in the
pathophysiologic process of cardiovascular
diseases such as atherosclerosis, heart fail-
ure, and atrial fibrillation is well
described.24,25 Distinct subsets of circulating
monocytes with a proinflammatory or repar-
ative phenotype have been identified in
humans and mouse models.21,26 The
elevated risk of cardiovascular death with
elevated neutrophil and monocyte counts
in our study may reflect ongoing myocardial
and vascular damage or dysregulated inflam-
mation in ambulatory adults without preex-
isting cardiovascular disease.
We also found that a low lymphocyte
count is not an independent risk factor for
cardiovascular mortality, in contrast to pre-
vious reports in advanced heart failure.27
The association of a lower lymphocyte count
with cardiovascular mortality was not
observed in the fully adjusted model, sug-
gesting that the adverse prognostic role of
decreased lymphocytes is likely to be medi-
ated (or modulated) by other covariates.
Increased cortisol production during stress
shifts the leukocyte production in favor of
neutrophils and monocytes over lympho-
cytes.28 This might explain why the
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neutrophil-lymphocyte ratio and MLR may
be a better marker of inflammation than ab-
solute neutrophil or monocyte count.
Elevated CRP is a widely used marker for
adverse cardiovascular outcomes, both in the
general population and in patients with car-
diovascular disease. Furthermore, CRP is the
most widely used inflammatory marker in
cardiovascular risk prediction models.7,8
The exact role of CRP in the pathogenesis
of cardiovascular diseases is not clear. In
atherosclerosis, it has been proposed that
some isoforms of CRP drive increased
expression of proinflammatory adhesion
molecules that mediate the migration of
monocytes to atheromatous plaques.29
Furthermore, activated monocytes in the
arterial wall have been reported to be critical
for hypertension-induced vascular remodel-
ing in humans.30 These observations
together with a weaker association between
CRP and cardiovascular mortality in our
study led us to speculate that CRP may not
reliably indicate tissue-level immune cell
recruitment and dysregulated responses
compared with circulating immune cells.
Another possibility is that CRP may not be
as reliable as MLR as a marker of nonathero-
sclerotic (such as heart failure and cardiome-
tabolic disease) myocardial insult.
Furthermore, the monocytes recruited to
the myocardium may be the final pathway
after myocardial damage leading to adverse
myocardial remodeling. Thus, monocytes
have a higher predictive value than lipopro-
teins that drive atherosclerosis and may asso-
ciate with the severity of atherosclerosis at
the time of measurement in those without
established cardiovascular disease.31,32 Our
study finds that MLR may be a better risk
prognosticator than CRP in those without
prevalent CVD while validating the associa-
tion of CRP with cardiovascular events.
Collectively, these conceivable but
hypothesis-generating observations may
explain the higher predictive value of the
MLR than of CRP and lipoproteins to predict
cardiovascular mortality in our study.
The adverse prognostic implications of
readily available circulating immune cell
markers for adverse cardiovascular outcomes
in healthy participants have been previously
reported in separate studies.1,3,7,8,10,11 Despite
their independent adverse prognostic role,
traditional risk prediction models, such as
the 10-year ASCVD risk score, do not include
any immune markers.6 To the best of our
knowledge, this is the first time that the rela-






































































































FIGURE 2. The relative predictive value of circulating immune markers to
predict CV mortality. The circulating immune markers are arranged in
decreasing order of importance. Likelihood ratio c2 using Cox Model to
predict CV mortality (panel A). Wald c2 using Cox Model to predict CV
mortality (panel B). The AUC using a logistic model to predict 10-year CV
mortality (panel C). Standardized domination statistic using a logistic model
to predict the relative importance of immune markers for 10-year CV
mortality (panel D).
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ratio and MLR, and CRP have been compared
in a single risk prediction model with an
established risk score to predict 10-year car-
diovascular mortality. Randomized controlled
trials have suggested a beneficial role of
immunomodulation in secondary prevention
to reduce adverse cardiovascular events.33,34
Future studies in other prospective cohorts
are needed to validate these findings and to
investigate whether immunomodulation has
a role in the primary prevention of cardiovas-
cular disease in individuals with a cardioin-
flammatory phenotype. Immune markers,
such as MLR, can help identify a subset of pa-
tients without cardiovascular disease who may
benefit from immunomodulation.
Our study has important limitations. The
baseline values of circulating immune
markers were used in the prediction model.
We could not correlate temporal trends of
immune markers with cardiovascular mor-
tality because of a lack of serial measure-
ments in the NHANES. Even though we
excluded participants with leukocyte counts
outside the normal range, the measures of
circulating immune markers could have
been confounded by an acute illness at the
time of enrollment. We used a self-reported
history of heart attack, angina, coronary
heart disease, heart failure, stroke, and
pacemaker at baseline to exclude patients
with preexisting cardiovascular disease that
may have resulted in bias. However, previ-
ous data show good reliability and validity
of self-reported comorbidities in the
NHANES data.35 In the study population,
41% of participants were outside the age
range of ASCVD (<40 years or >79 years);
the 10-year ASCVD risk score estimation in
these participants may have overestimated
Unadjusted HR 2.60 (2.23, 3.05), P<.001
































Unadjusted HR 2.47 (2.11, 2.90), P<.001

































FIGURE 3. Risk of cardiovascular mortality stratified by monocyte-lymphocyte ratio (MLR) in the Cox proportional hazards model (A)
and competing risk regression model with noncardiovascular mortality as competing risk (B) adjusted for age, sex, race, hypertension,
hemoglobin, diabetes mellitus, chronic obstructive pulmonary disease, current smoking, dyslipidemia, estimated glomerular filtration
rate, malignant disease, obesity, and National Health and Nutrition Examination Survey cycle. HR, hazard ratio.
Incidence rate ratio 1.13



























FIGURE 4. Dose-response relationship be-
tween monocyte-lymphocyte ratio and cardio-
vascular mortality. The solid green line
represents the incidence rate, and the dashed
green lines represent the 95% confidence
interval (CI). There was a linear increase in the
risk of cardiovascular mortality with increase in
the monocyte-lymphocyte ratio.
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or underestimated the cardiovascular risk.
The 10-year ASCVD risk score predicts
future risk of nonfatal myocardial infarction
or coronary heart disease death or fatal or
nonfatal stroke during 10 years.6 However,
because of the lack of other outcomes in
the NHANES, we used cardiovascular mor-
tality as an outcome, and it is plausible
that the 10-year ASCVD risk score overesti-
mated the risk. However, the fact that the
up-classification of risk of cardiovascular
mortality was better than the ASCVD score
indicates that it is unlikely that the results
observed in our study were simply due to
overestimation of risk.
CONCLUSION
Several circulating immune markers are
independently associated with cardiovascu-
lar mortality in ambulatory US adults. The
MLR has the best predictive value for cardio-
vascular mortality among readily available
circulating immune markers. Further study
is needed to confirm our findings and to un-
derstand the pathobiologic mechanism link-
ing immune cells and cardiovascular risk.
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